Main Uses of Adenuric

Adenuric is a medication primarily used to treat chronic forms of hyperuricemia, a condition characterized by an excess of uric acid in the blood. It is specifically indicated for patients who have already developed deposits of urate crystals in the body, which can manifest as gouty arthritis or tophi.

The medication works by inhibiting xanthine oxidase, an enzyme responsible for the production of uric acid. By reducing the production of this acid, the medication helps to lower and maintain serum uric acid levels within a target range.

Conditions Treated

• Chronic Gout: It is used to manage gout when there is evidence of urate deposition.
• Hyperuricemia: It treats persistently high levels of uric acid to prevent the further formation of crystals.

Benefits and Long-term Management

The primary goal of treatment with Adenuric is to reduce the concentration of uric acid enough to allow existing urate crystals to dissolve over time and to prevent new crystals from forming.

Key Benefits

• Reduction of Urate Deposits: Consistent lowering of uric acid levels helps in the gradual dissolution of tophi (stiff nodules of urate crystals).
• Prevention of Joint Damage: By controlling crystal formation, the medication helps to limit the progressive joint destruction associated with chronic gout.
• Stabilization of Blood Chemistry: It provides a therapeutic option for maintaining stable uric acid levels in patients who require long-term management of hyperuricemia.

Regulatory References

1. European Medicines Agency overview of Adenuric

This section outlines the official population eligibility and exclusion criteria for Adenuric (febuxostat) as defined by governmental regulatory authorities.

Populations for Whom Use is Prohibited or Restricted

Organ and Reproductive Status Limitations

• Severe Renal Impairment: Use in severe impairment (creatinine clearance <30 mL/ min) has not been fully evaluated; in some regions, the dosage is limited to 40 mg once daily.
• Severe Hepatic Impairment: Safety and efficacy have not been studied in severe hepatic impairment (Child-Pugh Class C); caution must be exercised.
• Pregnancy and Breastfeeding: Use is not recommended during pregnancy or breastfeeding due to insufficient data or potential risk to the infant, respectively.

The interaction profile for Аденурик (Febuxostat) is primarily governed by its inhibitory effect on the Xanthine Oxidase (XO) enzyme. This mechanism establishes several restrictions explicitly documented in regulatory labels.

Co-administration with other XO substrates, specifically Azathioprine, Mercaptopurine, and Theophylline, is strictly contraindicated or prohibited by authorities, as this interaction causes an excessive and unsafe increase in the plasma concentrations and systemic exposure of these co-administered drugs.

Other interaction statements focus on potential exposure modifications. The co-administration of Febuxostat with Probenecid may increase the clearance of Febuxostat, a pharmacokinetic interaction noted for potentially reducing the drug's effectiveness. Similarly, the use of potent enzyme inducers may lead to a decrease in Febuxostat plasma levels.

Conversely, co-administration with substances like Naproxen or Ciclosporin results in no clinically significant exposure changes, as documented by the FDA and EMA. Administration can be taken without regard to food, as no relevant food interaction is documented. Interaction patterns are noted as potentially more pronounced in patients with severe renal impairment.

Selective Suppression of Uric Acid Production

Аденурик (Febuxostat) is a highly active, non-purine selective inhibitor that targets the enzyme Xanthine Oxidase (XO). This enzyme is solely responsible for catalyzing the final steps of the purine catabolism pathway, converting precursor molecules into uric acid. The mechanism relies on a tight, non-competitive blockade of the XO enzyme, stopping uric acid synthesis at its source and interrupting the final production of uric acid.

Dual-Form Blockade and Urate Crystal Dissolution

The mechanism ensures consistent suppression by inhibiting both the oxidized and reduced forms of the Xanthine Oxidoreductase enzyme. The primary physiological consequence of this sustained blockade is a sustained reduction in serum uric acid (sUA) concentration. This persistent low sUA environment promotes the necessary chemical equilibrium for the dissolution and reabsorption of stored urate crystals from body tissues over time, thereby reducing the concentration gradient that sustains urate crystallization.

Instruction Map: How to use Аденурик — Official Administration Guidelines

The administration of Аденурик (Febuxostat) is governed by specific protocols designed for the long-term, chronic management of hyperuricemia. The use follows the established instructions regarding dosage, frequency, and administration context.

Population-Specific Instructions

For patients with severe renal impairment (creatinine clearance < 30 mL/min), the dosage is limited to 40 mg once daily. No specific dose adjustment is required for older adults or individuals with mild to moderate renal or hepatic impairment.

Connection to the Overall Use Protocol

The administration follows a consistent, once-daily pattern with an initial titration phase to achieve therapeutic concentration targets. This protocol requires continuous adherence and specifies that treatment should not be interrupted if a gout flare occurs, reflecting the chronic nature of the prescribed use.

Research Evidence / Overview of Studies for Аденурик

Evidence for Managing Chronic Hyperuricaemia and Gout

This section summarizes the randomized controlled trials (RCTs) and systematic reviews that examined the compound's use for the long-term approach to high uric acid levels in adults with gout, focusing on study types and measured clinical endpoints.

The primary research base consists of multiple RCTs that compared the compound against both a placebo and allopurinol, the established standard of care. Studies evaluated patients with chronic hyperuricaemia and gout, a condition where symptoms may vary in intensity. The research explored study outcomes related to physical discomfort by monitoring the frequency of gout flares and tracking changes in the size and presence of tophi (urate crystal deposits). Findings describe patterns observed across the studies related to the achievement of low urate levels across the different regimens that were evaluated in the trials.

Evidence for Preventing Hyperuricaemia in Tumor Lysis Syndrome (TLS)

This part details the structure and short-term scope of the research that was conducted to evaluate the compound’s use for the acute approach to rapid uric acid elevation during chemotherapy in specific, high-risk patient groups.

The evidence for this use comes primarily from Randomized, Double-Blind Pivotal Trials. The research evaluated short-term or episodic symptom patterns in adult patients with blood cancers who were at intermediate to high risk of developing TLS following chemotherapy. The research monitored outcomes by tracking the body’s acute uric acid level measurements in the blood and the incidence of laboratory-defined and clinical TLS diagnosis.

Research Gaps and Areas of Scientific Uncertainty

Long-term Safety Surveillance Trials tracked outcomes over several years. Findings from these extended studies were not uniform regarding Cardiovascular Mortality. Due to these varying results, the certainty remains low regarding the comparative long-term outcomes over the longest follow-up durations. Furthermore, data for certain subgroups remain insufficient, and specific pediatric populations were not the primary focus of the initial major clinical trials. Research provides context but not individual predictions, and evidence highlights what is known—and what is still uncertain.

Common questions about Аденурик (FAQ)

Q: Can I take this medication if I have a history of liver problems?

Official product information contains special warnings and precautions for use in individuals who have pre-existing liver problems, sometimes referred to as hepatic impairment. Regulatory documents may suggest specific monitoring or dosage adjustments for these patients. Regulatory documents indicate that these conditions should be discussed with a healthcare professional.

Q: What happens if I miss a dose of the medication?

Regulatory instructions for use include specific advice on managing a missed dose. This guidance generally states whether to skip the forgotten dose and continue the regular schedule, or take the missed dose as soon as remembered, depending on the timing of the next dose. The guidance in the official patient information leaflet should be followed.

Q: Is this drug effective for treating muscle pain or only headaches?

The drug is only officially authorized and indicated for the specific conditions listed in the regulatory documents, such as the treatment of headaches. If a condition like muscle pain is not listed as an approved use (an 'indication'), then that use falls outside the authorized marketing approval. Official information only supports the uses explicitly approved by regulatory authorities.

Q: How long is this medicine authorized for use?

Regulatory documents specify the authorized duration of use or the maximum recommended treatment period for the indicated conditions. This information is based on clinical data and addresses risks potentially associated with prolonged use. Warnings about potential risks following extended periods of treatment are also detailed in the official safety information.

Q: Can I use this medication with a specific herbal supplement like St. John's Wort?

Official labeling, such as the Interactions section, lists known interactions between the medicine and other products, including specific herbal supplements. If a potential interaction is documented, the information will detail the necessary precautions or if the combination should be avoided according to the regulatory filing.

Q: What is the long-term safety profile of this medicine?

The official safety profile, which often includes information relevant to long-term use, summarizes all documented adverse events (undesirable effects) observed in clinical studies and during post-marketing surveillance. This collective data details the known risks and contributes to the overall understanding of the medicine's safety over time.

Storage and Disposal of Adenuric (Febuxostat)

Official storage requirements for Adenuric (febuxostat) tablets vary by region. The European Summary of Product Characteristics states that no special storage conditions are required. However, US labeling for equivalent febuxostat products specifies storing at 20 C to 25 C (68 F to 77 F), and the product must be protected from light.

The medication has a labeled shelf life of 3 years and must always be kept out of the sight and reach of children.

For disposal, the European label states no special requirements. In the US, it is recommended to dispose of unused product according to local regulations, which typically means avoiding disposal in wastewater or household trash.